BioNTech Completes CureVac Acquisition, Ending Independent Trading Era
12.01.2026 - 09:55:04 | boerse-global.de
The era of CureVac as a publicly traded company has concluded. BioNTech SE has finalized its acquisition of the mRNA pioneer, removing CureVac’s shares from the Nasdaq exchange. The move transforms the long-competitive firm into a fully integrated subsidiary, bringing all its patents, manufacturing capabilities, and associated legal matters under BioNTech’s corporate umbrella. For former shareholders, the financial chapter is closed, while BioNTech now enters a critical operational integration phase.
Through this transaction, BioNTech secures several key strategic components from CureVac. These include a state-of-the-art production facility located in Tübingen, Germany, and proprietary “RNA Printer” modules designed for automated mRNA vaccine manufacturing. The acquisition also delivers CureVac’s Read more...
So schätzen die Börsenprofis BioNTech Aktien ein!
Für. Immer. Kostenlos.
